• search
Drug Product Formulation Development Services Drug Product Formulation Development Services

Drug Product Formulation Development Services

We offer one stop solution for drug product development of oral, parenteral and topical dosage forms.

We offer drug product development through a highly skilled scientific team with expertise in variety of dosage forms like oral, parenteral and topical. We specialize in pediatric dosage forms, fixed dose combinations and modified-release dosage forms. We also support for development of customized formulations for animals. Our team has extensive experience in developing complex formulations and provide tailored solutions to optimize the development time and costs. 

Our team is committed to delivering quality results in a time-bound and cost-effective manner at each stage of the development process. Customers also select us, to evaluate container closure systems, storage, and transportation conditions. 

ICH-compliant stability studies along with a range of conditions to cover various climatic zones across the globe, help in making decisions early in the drug development cycle. 

With decades of experience in formulation development, our scientists look forward to accelerating the time to market of your molecule.

Speak to our experts

Solid Orals

  • Immediate-release tablets (chewable tablets, orally disintegrating tablets, sublingual tablets and bi-layer tablets)
  • Modified release tablets (Monolayer, bilayer and mini tablets)
  • Fixed dose combinations (Monolayer, Bilayer and Multi particulate systems (Granules, pellets or mini-tablets and combinations thereof)
  • Hard Capsules (Hard gelatin or Cellulose capsules with powder in capsule, pellets in capsules) and soft gelatin capsules
  • Multi-particulate systems (Pellets and mini tablets)
  • Powder in sachet for solution/suspension

Oral Liquids

  • Oral solutions with dosing cup
  • Oral drops with dosing device
  • Oral suspension
  • Oral emulsions


  • Liquid injectables
  • Lyophilized injectables
  • Complex injectables
  • Ophthalmic and otic solutions
  • Nasal solutions ( Sprays and Blow-Fill-Seal)


  • Ointment
  • Cream
  • Gel

Why Aurigene Pharmaceutical Services?

Services across the product lifecycle

USFDA inspected lab and manufacturing facilities

Experience with advanced formulation technologies

20+ years of experience in formulation

Virtual Tour

Oligonucleotide as a novel class of therapeutic modality

JULY 02, 2021

Oligonucleotide as a novel class of therapeutic modality

Oligonucleotides as a therapeutic class is a revolutionary approach to discover new and important therapeutic agents for treating human diseases. RNA-based intervention at times works in cases where other modalities do not work. For example, it may help in treating inborn errors in metabolism, genetic disorders and rareOligonucleotide therapeutics is the use of c...

Read More

Accelerating Drug Discovery Through Innovative Partnerships

Genomics plays a vital role in identifying which gene is associated with a specific disease. A gene called CNOT1 is for example known for it's effect on brain development and for impairing memory and learning. Despite the great promise genomics provides in understanding the disease, genes are not the best drug targets....

Read More

Expediting early development through innovative precision capsule filling technology

Introduction: Any new chemical entity (NCE) needs to undergo various stages of development such as preclinical and clinical trials before drug product is approved by regulatory agencies and available for patient. Formulations developed during early phases are simple formulations to enable phase appropriate studies like screening, dose ranging, toxicological and d...

Read More

Synthesis of 2-hydroxy-3-alkyl-2-phenyl-2,3- dihydroquinazolin-4(1H)-one via molybdenum hexacarbonyl mediated CO gas- and ligand free carbonylative reactions


Carbon monoxide gas and ligand-free conditions were developed for the synthesis of 2-hydroxy-3-alkyl-2-phenyl-2,3-dihydroquinazolin4(1H)-one via catalytic carbonylation with molybdenum hexacarbonyl as an efficient carbonylating agent for the three-component reaction of isatoic anhydride, amine, iodobenzene. Mo(CO)6 is a solid carbon monoxide source. The quinazoli...

Read More
View All

You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.

If you wish to continue to this external website, click Proceed.